Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04675333
Title ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ALX Oncology Inc.
Indications

head and neck squamous cell carcinoma

Therapies

Carboplatin + Evorpacept + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil + Pembrolizumab

Carboplatin + Fluorouracil + Pembrolizumab

Cisplatin + Evorpacept + Fluorouracil + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ESP | BEL

Facility Status City State Zip Country Details
Hoag Hospital Recruiting Irvine California 92618 United States Details
University of California San Diego Recruiting La Jolla California 92037 United States Details
Sylvester Comprehensive Cancer Center Recruiting Miami Florida 33136 United States Details
Rush University Medical Center Recruiting Chicago Illinois 60612 United States Details
University of Louisville Recruiting Louisville Kentucky 40202 United States Details
University of Maryland Medical System Recruiting Baltimore Maryland 21201 United States Details
Vanderbilt - Ingram Cancer Center Recruiting Nashville Tennessee 37232 United States Details
Ashford Cancer Centre Recruiting Adelaide South Australia 5037 Australia Details
Cliniques Universitaires Saint-Luc Recruiting Bruxelles Belgium Details
Hospital Universitari Dexeus Recruiting Barcelona 08028 Spain Details
Hospital Universitario La Paz Recruiting Madrid Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field